Tag: orsiro

ESC 2019: Ultrathin strut Orsiro better than thin strut Xience for...

One-year data from the BIOSTEMI study, simultaneously published in The Lancet and presented at the European Society of Cardiology Congress (ESC 2019; 31 August–4...

EuroPCR 2019: Ultrathin stent demonstrates benefits in small vessels

Late-breaking trial data presented at EuroPCR 2019 (20–24 May, Paris, France) on three year outcomes of a substudy of patients with small vessel disease...

CRT 2019: Three-year data shows trend towards lower target vessel failure...

Three-year outcome data from the BIO-RESORT randomised controlled trial, which were presented at the 2019 Cardiovascular Research Technologies (CRT) meeting (2–5 March, Washington, DC,...

FDA approves Orsiro for use in the USA

  The US FDA have approved Biotronik’s drug-eluting stent Orsiro. A press release states that Orsiro is the first and only ultrathin drug-eluting stent to...

Orsiro may be the new benchmark for comparison in drug-eluting stent...

At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) meeting (21–25 September, San Diego, USA), David Kandzari (Piedmont Heart Institute, Atlanta, USA) presented the two-year results...

TCT 2018: Orsiro continues to have lower rates of target lesion...

Two-year data from the BIOFLOW-V randomised trial—which compared a sirolimus stent with a biodegradable polymer (Orsiro, Biotronik) with a everoliums-eluting stent with a permanent...

TCT 2018: Lower rate of stent thrombosis with Resolute Onyx vs....

Data presented yesterday at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) meeting (21-25 September, San Diego, USA) indicate that there were no significant differences in...

ESC 2018: Higher all-cause mortality with Orsiro at five years than...

According to the five-year results of the BIOSCIENCE trial, sirolimus-eluting stents with a biodegradable polymer (Orsiro, Biotronik) have a similar overall safety and efficacy...

EuroPCR 2018: One- to two-year landmark analysis shows significantly lower target...

Two-year outcome data from the BIO-RESORT randomised controlled trial, which were presented in a late-breaking clinical trials session by Marlies M Kok (Thoraxcentrum Twente,...

CIT 2018: BIOFLOW-VI confirms non-inferiority of Orsiro to Xience

Nine and 12-month data for Orsiro—presented by Yang Yue Jin (Fu-Wai Hospital, National Center of Cardiovascular Disease, Beijing, China) at the China Interventional Therapeutics...

Enrolment complete in BIOSTEMI study

Biotronik has announced that patient enrolment for the BIOSTEMI study has been completed. A press release explains that BIOSTEMI—a randomised, controlled superiority study—is the...

Japanese Ministry of Health approve Biotronik’s Orsiro drug-eluting stent

According to a Biotronik press release, the Japanese Ministry of Health has approved the company’s Orsiro coronary stent—a sirolimus-eluting stent with a biodegradable polymer—for...

ESC 2017: Significantly lower event rates with Orsiro than with Xience

  Results from the BIOFLOW V study indicate that patients who undergo percutaneous coronary intervention (PCI) using a sirolimus-eluting stent with a biodegradable polymer (Orsiro,...

BIOFLOW-IV confirms non-inferiority of Biotronik’s Orsiro in Japan

The 12-month results of Biotronik’s BIOFLOW-IV multicentre clinical study have been presented at the 2-17 Japan Circulation Society congress (JCS; 17-19 March, Kanazawa, Japan)....

TCT 2016: All comers study finds no differences between Orsiro, Synergy...

BIO-RESORT, presented at TCT today during a late-breaking trial session, has found no significant differences at one year between Medtronic's Resolute Integrity (a durable...

Risk of device thrombosis may be significantly higher with Absorb than...

A network meta-analysis, published in JACC: Cardiovascular Interventions, indicates that three contemporary drug-eluting stents—Xience (a cobalt-chromium everolimus-eluting stent; Abbott Vascular), Promus (a platinum-chromium everolimus-eluting...